DIFFERENTIATION OF CAUSES OF RIGHT HEART FAILURE
The present invention relates to the field of diagnostic means and methods. More specifically, the present invention relates to a method of differentiating between pulmonary embolism and pulmonary hypertension as the cause of right heart failure in a subject comprising determining the amounts of a natriuretic peptide, a cardiac troponin, GDF-15 and endoglin in a sample of a subject suffering from right heart failure and comparing the amounts with reference amounts, whereby it is differentiated between pulmonary embolism and pulmonary hypertension as the cause of the right heart failure. Furthermore, the present invention relates to methods of determining whether a subject suffering from right heart failure is susceptible to a therapy for pulmonary hypertension or pulmonary embolism as well as to a diagnostic device and a diagnostic kit adapted for carrying out the method of the present invention.
1 . A method of differentiating between pulmonary embolism and pulmonary hypertension as a cause of right heart failure in a subject, the method comprising
determining an amount of a natriuretic peptide, an amount of a cardiac troponin, an amount of growth differentiation factor-15 (GDF-15), and an amount of endoglin in a sample from a subject suffering from right heart failure, and
comparing the amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin determined with reference amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin, respectively,
wherein determined amounts of the natriuretic peptide, the cardiac troponin, and GDF-15 larger than or equal to the reference amounts of the natriuretic peptide, the cardiac troponin, and GDF-15 and a determined amount of endoglin less than the reference amount of endoglin are indicative for pulmonary embolism as the cause of the right heart failure, and
wherein determined amounts of the natriuretic peptide, the cardiac troponin, and GDF-15 less than the reference amounts of the natriuretic peptide, the cardiac troponin, and GDF-15 and a determined amount of endoglin larger than or equal to the reference amount of endoglin are indicative for pulmonary hypertension as the cause of the right heart failure.
2 . The method of claim 1 , wherein the reference amount of the natriuretic peptide is 2500 pg/ml, the reference amount of the cardiac troponin is 50 pg/ml, the reference amount of GDF-15 is 2000 pg/ml and the reference amount of endoglin is 5 ng/ml.
3 . The method of claim 1 , wherein the natriuretic peptide is NT-proBNP.
4 . The method of claim 1 , wherein the cardiac troponin is troponin T.
5 . A method of determining whether a subject suffering from right heart failure is susceptible to a therapy for pulmonary hypertension comprising the steps of
determining an amount of a natriuretic peptide, an amount of a cardiac troponin, an amount of growth differentiation factor-15 (GDF-15), and an amount of endoglin in a sample from a subject suffering from right heart failure, and
comparing the amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin determined with reference amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin, respectively, whereby pulmonary embolism and pulmonary hypertension are differentiated as the cause of the right heart failure, and
identifying the subject as susceptible to a therapy for pulmonary hypertension if pulmonary hypertension is determined as a cause of the right heart failure.
6 . The method of claim 5 , wherein said therapy for pulmonary hypertension is selected from the group consisting of vasodilator therapies, anti-inflammatory therapies, remodelling therapies, inhalation therapies, anticoagulant therapies, and antiplatelet therapies.
7 . A method of determining whether a subject suffering from right heart failure is susceptible to a therapy for pulmonary embolism comprising the steps of
determining an amount of a natriuretic peptide, an amount of a cardiac troponin, an amount of growth differentiation factor-15 (GDF-15), and an amount of endoglin in a sample from a subject suffering from right heart failure, and
comparing the amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin determined with reference amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin, respectively, whereby pulmonary embolism and pulmonary hypertension are differentiated as the cause of the right heart failure, and
identifying the subject as susceptible to a therapy for pulmonary embolism if pulmonary embolism is determined as a cause of the right heart failure.
8 . The method of claim 7 , wherein said therapy for pulmonary embolism is a drug-based thrombolytic therapy or a surgery-based therapy.
9 . A device for differentiating between pulmonary embolism and pulmonary hypertension as the cause of right heart failure in a subject comprising:
means for determining the amounts of a natriuretic peptide, a cardiac troponin, GDF-15 and endoglin in a sample of a subject suffering from right heart failure, and
means for comparing the amounts determined with reference amounts, whereby pulmonary embolism and pulmonary hypertension are differentiated as the cause of the right heart failure.
10 . A kit for differentiating between pulmonary embolism and pulmonary hypertension as a cause of right heart failure in a subject, the kit comprising:
instructions for differentiating between pulmonary embolism and pulmonary hypertension as a cause of right heart failure in the subject,
means for determining the amounts of a natriuretic peptide, a cardiac troponin, GDF-15, and endoglin in a sample from the subject, and
means for comparing the amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin determined with reference amounts of the natriuretic peptide, the cardiac troponin, the GDF-15, and the endoglin, respectively, whereby pulmonary embolism and pulmonary hypertension are differentiated as the cause of the right heart failure.